These results highlight a JMJD2A-ETV1-YAP1 crosstalk associated with PCa initiation, and thus, it could represent a suitable target for therapeutic management of PCa patients (Kim et al., 2016). The gene discussed is YAP1; the disease is posterior cortical atrophy.